Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Genotyping of CYP2D6 in Parkinson's disease
Autore:
Stefanovic, M; Topic, E; Ivanisevic, AM; Relja, M; Korsic, M;
Indirizzi:
Sestre Milosrdnice Univ Hosp, Clin Inst Chem, HR-10000 Zagreb, Croatia Sestre Milosrdnice Univ Hosp Zagreb Croatia HR-10000 000 Zagreb, Croatia Univ Zagreb, Sch Med, Inst Clin Chem, Zagreb 41001, Croatia Univ Zagreb Zagreb Croatia 41001 , Inst Clin Chem, Zagreb 41001, Croatia Univ Zagreb, Sch Med, Dept Neurol, Zagreb 41001, Croatia Univ Zagreb Zagreb Croatia 41001 Med, Dept Neurol, Zagreb 41001, Croatia Clin Hosp Ctr, Zagreb, Croatia Clin Hosp Ctr Zagreb CroatiaClin Hosp Ctr, Zagreb, Croatia
Titolo Testata:
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
fascicolo: 9, volume: 38, anno: 2000,
pagine: 929 - 934
SICI:
1434-6621(200009)38:9<929:GOCIPD>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
CYTOCHROME-P450 ENZYMES; POOR METABOLIZERS; DRUG-METABOLISM; POLYMORPHISM; GENE; ALLELE; PHENOTYPE; 2D6; PCR; METAANALYSIS;
Keywords:
CYP2D6 polymorphism; Parkinson's disease; Hoehn and Yahr staging; multiplex PCR;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Stefanovic, M Sestre Milosrdnice Univ Hosp, Clin Inst Chem, Vinogradska 29, HR-10000 Zagreb, Croatia Sestre Milosrdnice Univ Hosp Vinogradska 29 Zagreb Croatia HR-10000
Citazione:
M. Stefanovic et al., "Genotyping of CYP2D6 in Parkinson's disease", CLIN CH L M, 38(9), 2000, pp. 929-934

Abstract

Parkinson's disease is characterized by progressive degradation of dopaminergic: neurons. Cytochrome P450 CYP2D6 enzyme is one of the most investigated and highly polymorphic isoforms, which metabolizes many drugs and is also involved in the metabolism of dopamine. Using allele-specific multiplex PCR, we genotyped 186 subjects for CYP2D6 *3, *4, *6, *7, and *8 alleles in order to estimate allelic, genotype and predicted phenotype frequencies in the control and patient groups, and to investigate the possible statisticaldifference between Parkinson's disease patients (n=41) and healthy controls (n=145). Parkinson's disease patients were further divided into two subgroups according to Hoehn and Yahr staging of the disease (HY), i.e. groups with HY stage less than 2.5 (HY <2.5; n=27) and more than 2.5 (HY >2.5; n=14). A subgroup of Parkinson's disease patients exhibiting side effects such as "on-off" phenomenon and dyskinesia (both suggesting favorable response to therapy) were compared with a subgroup of patients showing no such response. The preliminary results of this study showed that only the prevalence of CYP2D6 *4 allele differed significantly between the PD patients and control group (20.7% vs. 11.0%; p=0.027; RR=2.1, 95%CI 1.113-3.994). In the HY >2.5 subgroup, the CYP2D6*4 allelic difference was even greater (25.0% vs. 11.0% in controls; p=0.062, RR=2.69, 95%CI 1.090-6.624). Genotype frequencies differed only in the HY >2.5 subgroup, however with a level of significance of p=0.095.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 08:09:27